Michael Rowbotham
Director/Board Member at The University of California, San Francisco
Michael Rowbotham active positions
| Companies | Position | Start | End |
|---|---|---|---|
| The University of California, San Francisco | Director/Board Member | - | - |
Career history of Michael Rowbotham
Former positions of Michael Rowbotham
| Companies | Position | Start | End |
|---|---|---|---|
| ADAMAS PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/05/2006 | - |
Training of Michael Rowbotham
| The University of California, San Francisco | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Statistics
International
| United States | 4 |
Operational
| Chief Tech/Sci/R&D Officer | 1 |
| Doctorate Degree | 1 |
| Director/Board Member | 1 |
Sectoral
| Consumer Services | 3 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 1 |
|---|---|
Adamas Pharmaceuticals LLC
 Adamas Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. | Health Technology |
- Stock Market
- Insiders
- Michael Rowbotham
- Experience
